513 related articles for article (PubMed ID: 33712536)
21. PSMA Ligands for PET Imaging of Prostate Cancer.
Schwarzenboeck SM; Rauscher I; Bluemel C; Fendler WP; Rowe SP; Pomper MG; Afshar-Oromieh A; Herrmann K; Eiber M
J Nucl Med; 2017 Oct; 58(10):1545-1552. PubMed ID: 28687599
[TBL] [Abstract][Full Text] [Related]
22. Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques.
Rowe LS; Harmon S; Horn A; Shankavaram U; Roy S; Ning H; Lindenberg L; Mena E; Citrin DE; Choyke P; Turkbey B
Radiat Oncol; 2021 Feb; 16(1):32. PubMed ID: 33568190
[TBL] [Abstract][Full Text] [Related]
23. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
24. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
[TBL] [Abstract][Full Text] [Related]
25. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
26. [
Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
[TBL] [Abstract][Full Text] [Related]
27. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
[No Abstract] [Full Text] [Related]
29. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.
Ravi Kumar AS; Lawrentschuk N; Hofman MS
Curr Opin Urol; 2020 Sep; 30(5):628-634. PubMed ID: 32701720
[TBL] [Abstract][Full Text] [Related]
31. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.
Koschel S; Murphy DG; Hofman MS; Wong LM
Curr Opin Urol; 2019 Nov; 29(6):569-577. PubMed ID: 31567440
[TBL] [Abstract][Full Text] [Related]
32. Phase I Study of CTT1057, an
Behr SC; Aggarwal R; VanBrocklin HF; Flavell RR; Gao K; Small EJ; Blecha J; Jivan S; Hope TA; Simko JP; Kurhanewicz J; Noworolski SM; Korn NJ; De Los Santos R; Cooperberg MR; Carroll PR; Nguyen HG; Greene KL; Langton-Webster B; Berkman CE; Seo Y
J Nucl Med; 2019 Jul; 60(7):910-916. PubMed ID: 30464040
[TBL] [Abstract][Full Text] [Related]
33. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
34. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
35. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
Maurer T; Gschwend JE; Eiber M
Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
[TBL] [Abstract][Full Text] [Related]
37. Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence-A Narrative Review of the Literature.
Ekmekcioglu Ö; Busstra M; Klass ND; Verzijlbergen F
J Nucl Med; 2019 Oct; 60(10):1394-1398. PubMed ID: 30850500
[No Abstract] [Full Text] [Related]
38. A comparative study of peptide-based imaging agents [
Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A
Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
[TBL] [Abstract][Full Text] [Related]
40. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]